Interstitial lung disease (ILD) refers to a large and heterogeneous group of more than 200 parenchymal disorders. ILDs have many causes, including connective tissue diseases, environmental factors, and some medications. Between 10% and 60% of those with fibrosing ILD will develop a progressive phenotype.
In this ReCAP, Dr Joshua Solomon from National Jewish Health in Denver, Colorado, discusses advances in the understanding of ILDs, specifically in the evolving phenotype of progressive pulmonary fibrosis (PPF), which falls outside of the well-defined definitions of idiopathic pulmonary fibrosis.
Dr Solomon underscores the need for early identification of potential progressive lung diseases so that patients may be treated for underlying causes. He also reports on the multimodality treatment approach, which includes medication, comorbidity management, and pulmonary rehabilitation. In addition, he emphasizes the need for immediate referral to specialty care for patients with suspected PPF.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Early Diagnosis and Treatment of Progressive Pulmonary Fibrosis - Medscape - Jul 05, 2022.
Comments